Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1769)	11/14/2003 1:45:04 PM
From: arnie h	Respond to of 2173

Thanks for your thoughts.

To: Miljenko Zuanic who wrote (1769)	11/25/2003 9:37:28 AM
From: arnie h	Read Replies (1) \| Respond to of 2173

Today's news. A full 1% is pretty decent and Lilly seems rather bullish about a mid-year filing. Wonder whether the high dose has any drawbacks. >SAN FRANCISCO (CBS.MW) -- Eli Lilly and Amylin Pharmaceuticals said late Monday that their drug exenatide, designed for people with type 2 diabetes, had shown positive results in the final stages of human testing. The two companies said all of the pivotal studies met the primary glucose control endpoint as measured by hemoglobin A1C, a measure that reflects the average level of glucose over the past three to four months. The average reduction in A1C in patients that took the highest dose of exenatide, or 10 micrograms twice daily, in the phase 3 trial, was about one percent. "We believe the data from the phase 3 program provide a solid base for a regulatory submission to the FDA, currently projected for mid-2004," said Elizabeth Klimes, president of Diabetes Care and Growth Disorders at Lilly.>